



DAFTAR PUSTAKA

- Alzheimer Society United Kingdom, 2020, Alzheimer's Society's view on demography, <https://www.alzheimers.org.uk/about-us/policy-and-influencing/what-we-think/demography>, 10 Oktober 2022.
- Alzheimers's Association, 2023, Frontotemporal Dementia (FTD), <https://www.alz.org/media/documents/alzheimers-dementia-frontotemporal-dementia-ts.pdf>, 7 Februari 2023.
- Alzheimer's Association, 2020, Alzheimer's Disease Facts and Figures, *Alzheimers Dement* 2020;16(3):391
- Alzheimer's Indonesia, 2019, Statistik tentang Demensia, <https://alzi.or.id/statistik-tentang-demensia/>, 08 Oktober 2022.
- Anonim, 2016, Demensia Indonesia, SmarPatient: Indonesia
- Anonim, 2022, Alzheimer's Disease and Related Dementiasbasics Of Alzheimer's Disease and Dementia, National Institutes of Health.
- Ariawan, I., 1998, Besar dan Metode Sampel ada Penelitian Kesehatan. Jurusan Biostatistik dan Kependudukan, Fakultas Kesehatan Masyarakat, Universitas Indonesia.
- Bansal, N., dan Parle, M., 2014, Dementia: An Overview, *Journal of Pharmaceutical Technology, Research and Management*, 2(1), pp. 29–45.
- Birks, J., dan Harvey, R. J., 2006, Donepezil for Dementia due to Alzheimer's Disease, *The Cochrane Database of Systematic Reviews*, 25(1), CD001190.
- Bott N.T., Radke A., Stephens M.L., 2014, Frontotemporal dementia: diagnosis, deficits and management. *Neurodegener Dis Manag*; 4: 439–454.
- Conway, M.E. Alzheimer's disease: targeting the glutamatergic system. *Biogerontology* 21, 257–274 (2020). <https://doi.org/10.1007/s10522-020-09860-4>
- Castro A., & Martinez A., 2006, Targeting Beta-Amyloid Pathogenesis Through Acetylcholinesterase Inhibitors, *Current Pharmaceutical Design*, 12(33), 4377–4387.
- Catindig, J.A.S., et al., 2012, Epidemiology of dementia in Asia: Insights on prevalence, trends and novel risk factors, *Journal of the Neurological Sciences*, 321(1–2), pp. 11–16.
- Ciolek, C.H., dan Lee, S.Y., 2020, Chapter 19 - *Cognitive Issues in the Older Adult*, in D. Avers and R.A. Wong (eds) *Guccione's Geriatric Physical Therapy* (Fourth Edition), St. Louis (MO): Mosby, pp. 425–452.



- Forester, B.P., dan Oxman, T.E., 2003, Measures to Assess the Noncognitive Symptoms of Dementia in the Primary Care Setting. *Prim Care Companion J Clin Psychiatry*, 5(4):158-163.
- Gustavo, C., RomÃ¡n, 2007, Chapter 47 - *Vascular Dementia*, Neurology and Clinical Neuroscience, Mosby, Pages 635-643.
- Hakiem, R.M., Gofir, A., Satiti, S., 2020, Patofisiologi normal pressure hydrocephalus, 19(1), p. 7.
- Husein, N., Lumempouw, S., Ramli, Y., 2010, Herqutanto, Uji validitas dan realibilitas Montreal cognitive assessment versi Indonesia (MoCA-Ina) untuk skrining gangguan fungsi kognitif, *Dalam Neurona, Majalah Kedokteran Neuro Sains*. Jakarta: Balai Penerbit FKUI: 27(4).
- Iemolo, F., Givanni, D., Claudia, R., Laura, C., Vladimir, H., Calogero, C., 2009, Review Pathophysiology of Vascular Dementia, *Biomed Central*, Canada, Vol.6. No.13.ppt:1-9.
- Ikawati, Z., 2011, *Farmakoterapi Sistem Saraf Pusat*, Bursa Ilmu, Yogyakarta.
- Imbimbo, B.P., Lombard, J. dan Pomara, N., 2005, Pathophysiology of Alzheimer's Disease, *Neuroimaging Clinics of North America*, 15(4), pp. 727–753.
- Indiyart, R., 2004, Diagnosis dan Pengobatan Terkini Demensia Vaskuler, *Jurnal Kedokteran Trisakti*, Jakarta, Vol.23. No.1, ppt:28-33.
- Kalaria, R.N., Maestre, G.E., Arizaga, R., Friedland, R.P., Galasko, D., Hall, K., Luchsinger, J.A., Ogunniyi, A., Perry, E.K., Potocnik, F., Prince, M., Stewart, R., Wimo, A., Zhang, Z.X., Antuono, P., 2008, Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors, *The Lancet Neurology*, 7(9), pp. 812–826.
- Kurz A., Kurz C., Ellis K., Lautenschlager, N. T., 2014, *What is frontotemporal dementia?* Maturitas, 79: 216–219.
- Lexicomp®, 2023, Donepezil, Diakses pada 13 April 2023 pukul 11.48 WIB.
- Lexicomp®, 2023, Memantine, Diakses pada 15 April 2023 pukul 12.38 WIB
- Ma, Y., Ji, J., Li, G., Yang, S., dan Pan, S., 2017, Effects of donepezil on cognitive functions and the expression level of β -amyloid in peripheral blood of patients with Alzheimer's disease, *Experimental and Therapeutic Medicine*.
- Maidment, I., Fox, C., dan Boustani, M., 2006, Cholinesterase Inhibitors for Parkinson's Disease Dementia, *The Cochrane Database of Systematic Reviews*, 25(1), CD004747.
- Mainland, Brian, Amodeo, Sean, Shulman, Kenneth, 2012, Clock Drawing Test. 10.1007/978-1-4471-2452-8_5.



- Marucci G., Buccioni M., Ben D. D., Lambertucci C., Volpini R., dan Amenta F., 2021, Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease, *Neuropharmacology*, 190, 108352.
- Mielech A., Puscion-Jakubik A., Markiewicz- Zukowska R., dan Socha K., 2020, Vitamins in Alzheimer's Disease—Review of the Latest Reports, *Nutrients*, 12, 3458
- Mitchell, A.J., 2009, A Meta-Analysis of The Accuracy of The Mini-Mental State Examination in The Detection of Dementia and Mild Cognitive Impairment, *Journal of Psychiatric Research*, 43(4), 411-431.
- Miyoshi, K., 2009, What is “early onset dementia”, *Psychogeriatrics*, 9(2), pp. 67–72.
- NICE, 2015, Dementia Interventions, <http://pathways.nice.org.uk/pathways/dementia#path=view%3A/pathways/dementia/dementia-interventions.xml&content=view-index>, 30 Oktober 2022.
- Pandey, S., Pandey, I., He, M., Paing, E., Pacheco, S., dan ULAB PHHS, 2021, Monotherapy vs Combination Therapy for the Management of Alzheimer's Disease, UC Berkeley: Public Health & Health Science Division. ULAB,
- Pedersen, W., 2007, Senile Dementia, in S.J. Enna dan D.B. Bylund (eds) xPharm: *The Comprehensive Pharmacology Reference*. New York: Elsevier, pp. 1–18.
- Plassman, B.L., Langa, K.M., Fisher, G.G., Heeringa, S.G., Weir, D.R., Ofstedal, M.B., Burke, J.R., Hurd, M.D., Potter, G.G., Rodgers, W.L., Steffens, D.C., Willis, R.J., Wallace, R.B., 2007, Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study, *Neuroepidemiology*, 29(1–2), pp. 125–132.
- Potocnik, Felix, 2013, Dementia. *South African Journal of Psychiatry*. 19. 141-152.
- Purba, J.S., 2012, *Penyakit Parkinson*, Jakarta: Badan Penerbit FKUI.
- Querfurth, H.W., dan LaFerla, F.M., 2010, Alzheimer's Disease, *New England Journal of Medicine*, 362(4), pp. 329–344.
- Rubenstein, D., Wayne, D. dan Bradley, J., 2003, *Lecture Notes: Kedokteran Klinis*, diterjemahkan oleh dr. Annisa Rahmalia, Edisi Keenam, Erlangga, Jakarta.
- Selkoe, D.J., 2006, Toward a Comprehensive Theory for Alzheimer's Disease, p. 9.
- Shams G. E.D. A. M., Khairy M. H., Saleh M. A., & Antar S. A., 2017, Adverse Effects of Memantine, *Zagazig Veterinary Journal*, 45(1), 221–234.



- Stephen, J., Richard, J.H. dan David, W., 2004, The Safety and Tolerability of Donepezil in Patients with Alzheimer's Disease, *British Journal Clinical Pharmacology*, 58(Suppl 1), 1-8.
- Bowie, Christopher dan Harvey, Philip, 2006, Administration and interpretation of Trail Making Test. *Nature protocols*. 1. 2277-81.
- Tampi, R.R., Williamson, D., Muralee, S., Mittal, V., McEnerney, N., Thomas, J., Cash, M., 2011, Behavioral and psychological symptoms of dementia: Part I- epidemiology, neurobiology, heritability and evaluation, *Clinical Geriatrics*, 19, 1-6.
- Vipin, A., Satish, V., Saffari, S.E., Koh, W., Lim, L., Silva, E., Nyu, M. M., Choong, T. M., Chua, E., Ng, A. S. L., Chiew, H. J., Ng, K. P., dan Kandiah, N., 2021, Dementia in Southeast Asia: influence of onset-type, education, and cerebrovascular disease, *Alz Res Therapy* 13, 195.
- Waldemar, G., et al., 2007, Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline, *European Journal of Neurology*, 14(1), pp. e1–e26.
- Wibowo, M.M., Karema, W. dan S, J. Maja. P., 2015, Gambaran Fungsi Kognitif Dengan Ina-Moca Dan Mmse Pada Penderita Post-Stroke Di Poliklinik Saraf Blu Rsup Kandou Manado November - Desember 2014, *e-CliniC*, 3(3).
- Wimo A, Guerchet M, Ali GC, Wu YT, Prina AM, Winblad B, Jönsson L, Liu Z, Prince M., 2017, The worldwide costs of dementia 2015 and comparisons with 2010. *Alzheimers Dement*, 13(1):1-7.
- World Health Organization, 2022, Dementia, <https://www.who.int/news-room/fact-sheets/detail/dementia>, 08 Oktober 2022.
- World Health Organization (1992) Dementia, Regional Office for the eastern Mediterranean.
- Yunusa I., & El Helou M. L., 2020, The Use of Risperidone in Behavioral and Psychological Symptoms of Dementia: A Review of Pharmacology, Clinical Evidence, Regulatory Approvals, and Off-Label Use, *Frontiers in Pharmacology*, 11, 596.